PD-1 is an immune checkpoint molecule, and the latest clinical trials on HCC have shown unprecedented success in immunotherapy targeting the PD-1/PD-L1 axis [53,54,55]. The gene discussed is CD274; the disease is hepatocellular carcinoma.